Axoft expands to 11 patients at three clinical sites including Mass General Brigham — new study announced
Summary
Axoft launched a new clinical research study with Mass General Brigham, expanding from the initial FINESSE study at The Panama Clinic to a US academic medical center. The company's total implantation count has grown to 11 patients across three different clinical sites. Axoft is concurrently developing a higher-bandwidth version of its Fleuron iBCI for longer-term neurodiagnostics and therapeutic applications, preparing for a second, more advanced clinical study.
Why it matters
Mass General Brigham partnering with Axoft brings the world's leading neurosurgery research network into the Fleuron BCI program. MGH's BrainGate collaboration history and neurosurgical expertise will accelerate the path from intraoperative feasibility to chronic implant clinical studies. Eleven patients across three sites represents significant clinical program scaling for an $18M company.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial